A Safety and Tolerability Study of AG-519 in Healthy Subjects

NCT02630927 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

108

Enrollment

INDUSTRY

Sponsor class

Stopped Agios is no longer developing its second pyruvate kinase-R (PKR) activator, AG-519, and withdrew its investigational new drug (IND) application in December 2016

Conditions

Anemia

Interventions

DRUG: AG-519
DRUG: Placebo

Sponsor

Agios Pharmaceuticals, Inc.